Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2015-02-17 Earnings Release
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM 6-K
Earnings Release Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bio Blast Pharma Ltd., with the SEC. It includes a press release announcing financial results for the fourth quarter ended December 31, 2014. Form 6-K filings typically contain interim or periodic updates but are not full annual reports. The document is short (1866 characters) and primarily serves as an announcement of financial results rather than a detailed report with substantive financial data. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only.
2015-02-17 English
SC 13G/A
Major Shareholding Notification
2015-02-13 English
6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bio Blast Pharma Ltd., with the SEC. It includes a Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of Shareholders. The content focuses on providing materials for a shareholder meeting and soliciting votes, which aligns with proxy solicitation materials. The document is relatively short (2026 characters) and does not contain financial statements or detailed financial analysis. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains the proxy materials themselves. The best fitting category is Proxy Solicitation & Information Statement (PSI).
2015-02-10 English
FORM 6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by Bio Blast Pharma Ltd., which is a report of a foreign private issuer submitted to the SEC. The content specifically mentions that it consists of a press release announcing key senior leadership changes. There is no detailed financial data, no annual or quarterly report, and no audit information. The document is short (1756 characters) and primarily serves as an announcement of management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the correct classification is MANG.
2015-02-02 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing preliminary clinical study findings. The document is short (1857 characters) and primarily serves as an announcement of information rather than a detailed financial or management report. It does not contain financial statements or detailed analysis. Form 6-K filings typically fall under Regulatory Filings (RNS) as they are miscellaneous reports submitted by foreign issuers that do not fit into other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-01-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Bio Blast Pharma Ltd., submitted to the SEC. It contains a press release announcing the issuance of a new patent by the USPTO. The document is short (1815 characters) and primarily serves as a regulatory announcement rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report content. According to the rules, such filings that are announcements or press releases submitted on Form 6-K are best classified under Regulatory Filings (RNS), as they do not fit into other specific report categories and are not full reports themselves.
2014-12-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.